Sun Pharmaceutical Industries has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with potential therapeutic activity across multiple indications in Sun Pharma’s specialty focus areas.
Under the terms of the license agreement, the company gets exclusive global license for the said patents and any other future patents covered in the agreement. The company will pay CSIR-IICT upfront and potential development, regulatory and sales milestone payments totaling up to Rs 2.40 billion, plus royalties on net sales from commercialization of the products developed using these patents. The company will be responsible for development, regulatory filings, manufacturing and commercialization of these potential products.
Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.05 |
Dr. Reddys Lab | 1354.20 |
Cipla | 1470.05 |
Lupin | 2190.50 |
Zydus Lifesciences | 1004.05 |
View more.. |